Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01782144
Other study ID # 12887
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2011
Est. completion date September 2011

Study information

Verified date October 2020
Source Temple University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obesity is a serious medical, social, and economic problem and is becoming even greater concern, as the prevalence of overweight and obese individuals has steadily increased over the years. Excessive body weight can have a profound influence on lower extremities, including pain, degenerative disease, and compromised quality of life. However, no study to-date has examined the effects of weight change on foot structure and function in individuals over time. The purpose of this study is to determine the effects of weight reduction on foot structure and function in obese adults. Improved understanding of the relationship between body weight and foot biomechanics is needed to promote health and healthier lifestyles.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria:

- Men and women between the ages of 50 to 75, inclusive

- Body Mass Index is = 30 kg/m2 but < 45 kg/m2 and body weight < 300 pounds

- Able to ambulate safely without the use of a walking aid (cane, crutches, or walker)

- Able to understand the information in the informed consent form and is willing and able to comply with the study-related procedures

Exclusion Criteria:

- Diabetes, stroke, end stage kidney disease requiring hemodialysis, or widespread malignant disease, gallbladder disease

- Severe peripheral vascular disease (defined as 1 < palpable pedal pulse and claudication pain in less than two blocks)

- Pregnant or nursing, as weight and hormonal changes during pregnancy may affect foot structure and function, which could confound the results of the study. Therefore, women who are pregnant or nursing will be excluded from the study.

- Not willing or able to make the required quarterly follow-up visits

- Insufficient (corrected) vision to complete the questionnaires

- Food allergies to the Nutrisystem, Inc. meal plan used in this protocol

- Participation in another formal weight loss program within last 6 months

- Uncontrolled hypertension (systolic blood pressure > 180 or diastolic blood pressure > 100 mmHg). Participants on medication treating hypertension for at least three months are allowable.

- Known atherosclerotic cardiovascular disease

- History of congestive heart failure

- History of a non-skin malignancy within the previous 5 years

- Any major active rheumatologic, pulmonary, hepatic, renal, dermatologic disease or inflammatory condition

Study Design


Related Conditions & MeSH terms


Intervention

Other:
NutriSystem portion-controlled pre-packaged meals


Locations

Country Name City State
United States Gait Study Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Temple University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Walking speed Change in walking speed at 3 month 3 months
Primary Postural stability Change in Fall Risk Test Score as measured by the BioDex Balance System. 3 months
Primary Peak plantar pressure Change in dynamic peak plantar pressure during barefoot walking. 3 months
Primary Instruments of pain and disability Change in answers on the following questionnaires: Revised Foot Function Index, the Medical Outcomes Study Short Form 36 (SF-36), Western Ontario and McMaster Universities Osteoarthritis Index. 3 months
Secondary Arch Height Drop Change in arch height in standing compared to sitting 3 months
Secondary Activities of Daily Living Change in 50' walk time and pain, stair ascend/descend time and pain, and sit-to-stand. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2